newsfilter
← Latest News
PR Newswire·

Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm

  • Kuehn Law, PLLC is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) for potential breaches of fiduciary duties by officers & directors.
  • A federal securities lawsuit alleges the company failed to disclose FDA concerns regarding the adequacy of clinical development for its lead drug candidate, relacorilant.
  • The company reportedly omitted that relacorilant's New Drug Application faced a material risk of rejection despite public claims of expected approval success.
  • Shareholders who purchased CORT stock prior to October 31, 2024, are invited to contact attorney Sophia Anne Silayan at [email protected] or (833) 672-0814.
  • Kuehn Law states it covers all case costs & charges no fees to investor clients.
  • The firm warns that there may be limited time to enforce shareholder rights & urges immediate contact.